|Bid||218.00 x 1200|
|Ask||233.92 x 1100|
|Day's Range||229.89 - 232.80|
|52 Week Range||194.51 - 236.29|
|PE Ratio (TTM)||38.84|
|Earnings Date||Oct 23, 2018 - Oct 29, 2018|
|Forward Dividend & Yield||0.68 (0.29%)|
|1y Target Est||251.43|
On a purely scientific level, nanotech involves any innovation conducted at the nanoscale, which is between one to 100 nanometers. Physicist Richard Feynman, during a lecture in December 1959, introduced the concept that future technologies would enable scientists to “manipulate and control individual atoms and molecules.” Over a decade later, professor Norio Taniguchi coined the term nanotechnology. A single sheet from a typical newspaper is approximately 100,000 nanometers thick.
During its Q2 2018 earnings release on July 25, Boston Scientific (BSX) updated its fiscal 2018 guidance. The company raised its fiscal 2018 sales guidance and maintained its adjusted EPS guidance at $1.37–$1.41, representing growth of 9%–12%.
Moody's Investors Service (Moody's) assigned a Baa2 rating to Thermo Fisher Scientific, Inc.'s ("Thermo Fisher") new E600 million of unsecured bonds. The issuer of these bonds will be Thermo Fisher Scientific (Finance I) B.V. The outlook remains stable. Proceeds from the bond offering will be used to refinance Thermo Fisher's E600 million bond due August 2018.
Wall Street analysts estimate Haemonetics’s (HAE) Q1 2019 revenues to increase ~4.3% to $219.9 million as compared to $210.9 million during Q1 2018. Also, the company is expected to report a net adjusted income of ~$20.0 million during Q1 2019.
In the second quarter, Boston Scientific’s adjusted EPS grew 28% YoY (year-over-year) to $0.41, exceeding its guidance of $0.33–$0.35. Boston Scientific’s strong earnings growth in the quarter was due to its strong profit and loss metrics. The company is working on improving cost efficiencies through its end-to-end business by streamlining and automation initiatives, expanding global shared services, and leveraging global sourcing teams. Peers Abbott Laboratories (ABT), Edwards Lifesciences (EW), and Thermo Fisher Scientific (TMO) reported adjusted EPS growth of 17.7%, 30.5%, and 19. ...
On July 25, Boston Scientific (BSX) released its Q2 2018 earnings results. It reported revenue of $2.49 billion, exceeding Wall Street’s estimate of ~$2.46 billion and coming in at the higher end of the company’s $2.45 billion–$2.5 billion guidance.
Shares of automotive companies climbed last Thursday as U.S. President Donald Trump eased the car tariff threat following a meeting with European Commission President Jean-Claude Juncker.
During Abbott Laboratories’ (ABT) second-quarter earnings release on July 18, the company increased its fiscal 2018 guidance. This move was triggered by the company’s strong performance in the quarter. ABT stock rose ~3.1% on the day of its earnings announcement.
CHICAGO , July 31, 2018 /PRNewswire/ -- AACC -- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, is showcasing its latest innovations for clinical and translational research ...
The Zacks Analyst Blog Highlights: Amazon, Facebook, Thermo Fisher, Home Depot and Progressive
Q2 Results: What Drove Its Robust Growth? On July 18, Abbott Laboratories reported its second-quarter adjusted diluted EPS of $0.73 during its earnings release. The company’s adjusted EPS represented YoY (year-over-year) growth of ~17.7%.
Abbott Laboratories (ABT) reported its second-quarter earnings on July 18. Its organic sales growth was ~8.0%, which was above the company’s guidance range. All four of the company’s business segments reported sales performance that exceeded expectations.
The U.S. Commerce Department deflected a Congressional committee’s concerns that it is doing an insufficient job stopping U.S.-made technology from playing a role in oppressive policing in China. Inc. were not subject to U.S. licensing rules that control the sale of crime-busting equipment to foreign countries.
Thermo Fisher’s Q2 2018 Earnings Surpass Analysts’ Estimates Thermo Fisher’s second-quarter earnings Leading pharmaceutical company Thermo Fisher Scientific (TMO) released its second-quarter earnings results today.
Thermo Fisher (TMO) is performing well on the back of a series of product launches along with major progress in precision medicine initiatives.
Thermo Fisher (TMO) delivered earnings and revenue surprises of 4.56% and 2.75%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?